Gautier Melchior, Joussellin Vincent, Ropers Jacques, El Houari Lina, Demoule Alexandre, Similowski Thomas, Combes Alain, Schmidt Matthieu, Dres Martin
Sorbonne Université, Institute of Cardiometabolism and Nutrition, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMRS) 1166, Paris, France.
Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Pitié-Salpêtrière, Paris, France.
Ann Intensive Care. 2023 Sep 26;13(1):92. doi: 10.1186/s13613-023-01179-w.
Venovenous extracorporeal membrane oxygenation (VV ECMO) is frequently associated with deep sedation and neuromuscular blockades, that may lead to diaphragm dysfunction. However, the prevalence, risk factors, and evolution of diaphragm dysfunction in patients with VV ECMO are unknown. We hypothesized that the prevalence of diaphragm dysfunction is high and that diaphragm activity influences diaphragm function changes.
Patients with acute respiratory distress syndrome (ARDS) requiring VV ECMO were included in two centers. Diaphragm function was serially assessed by measuring the tracheal pressure in response to phrenic nerve stimulation (Ptr,stim) from ECMO initiation (Day 1) until ECMO weaning. Diaphragm activity was estimated from the percentage of spontaneous breathing ventilation and by measuring the diaphragm thickening fraction (TFdi) with ultrasound.
Sixty-three patients were included after a median of 4 days (3-6) of invasive mechanical ventilation. Diaphragm dysfunction, defined by Ptr, stim ≤ 11 cmHO, was present in 39 patients (62%) on Day 1 of ECMO. Diaphragm function did not change over the study period and was not influenced by the percentage of spontaneous breathing ventilation or the TFdi during the 1 week. Among the 63 patients enrolled in the study, 24 (38%) were still alive at the end of the study period (60 days).
Sixty-two percent of patients undergoing ECMO for ARDS related to SARS CoV-2 infection had a diaphragm dysfunction on Day 1 of ECMO initiation. Diaphragm function remains stable over time and was not associated with the percentage of time with spontaneous breathing.
gov Identifier NCT04613752 (date of registration February 15, 2021).
静脉-静脉体外膜肺氧合(VV ECMO)常与深度镇静和神经肌肉阻滞相关,这可能导致膈肌功能障碍。然而,VV ECMO患者膈肌功能障碍的患病率、危险因素及演变情况尚不清楚。我们推测膈肌功能障碍的患病率很高,且膈肌活动会影响膈肌功能变化。
两个中心纳入了需要VV ECMO的急性呼吸窘迫综合征(ARDS)患者。从开始ECMO(第1天)至ECMO撤机,通过测量膈神经刺激后的气管压力(Ptr,stim)对膈肌功能进行连续评估。通过自主呼吸通气百分比和超声测量膈肌增厚分数(TFdi)来评估膈肌活动。
63例患者在有创机械通气中位时间4天(3 - 6天)后纳入研究。在ECMO第1天,39例患者(62%)存在膈肌功能障碍,定义为Ptr,stim≤11 cmH₂O。在研究期间,膈肌功能未发生变化,且在1周内不受自主呼吸通气百分比或TFdi的影响。在纳入研究的63例患者中,24例(38%)在研究期结束时(60天)仍存活。
因新型冠状病毒2型(SARS CoV - 2)感染相关ARDS接受ECMO治疗的患者中,62%在开始ECMO第1天存在膈肌功能障碍。膈肌功能随时间保持稳定,且与自主呼吸时间百分比无关。
美国国立医学图书馆临床试验注册中心标识符NCT04613752(注册日期2021年2月15日)